Andalay Solar, Inc. WEST 深 沪
已收盘 12-19 16:00:00 美东时间
4.19
-0.060
-1.41%
华盛通- 最 高4.3082
- 今 开4.22
- 成交量 72.04万股
- 最 低 4.19
- 昨 收 4.25
- 总市值 3.97亿
- 52周最高 7.92
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 3.59
- 委 比 40.91%
- 总股本 9470.81万
- 历史最高 14.71
- 量 比 1.02
- 振 幅 2.78%
- 历史最低 3.59
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
电话会总结 ｜ Westrock Coffee(WEST)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Westrock Coffee业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 合并净销售额同比增长61%，主要受益于销量增长和原材料成本上涨的传导 - 饮料解决方案部门净销售额同比增长60% - 可持续采购与追溯(SS&T)部门净销售额同比增长62% **盈利能力：** - 合并调整后EBITDA达到2,320万美元，同比增长125% - 合并分部调整后EBITDA达到2,620万美元，环比增长14%，同比增长84% - 饮料解决方案部门调整后EBITDA为2,040万美元，同比增长74% - SS&T部门调整
11-07 12:16
Westrock Coffee shares are trading higher after the company reported better-than-expected Q3 sales results.
Westrock Coffee shares are trading higher after the company reported better-tha...
11-07 06:01
Westrock Coffee Q3 EPS $(0.20) Misses $(0.08) Estimate, Sales $354.825M Beat $281.540M Estimate
Westrock Coffee (NASDAQ:WEST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.08) by 140.96 percent. This is a 300 percent decrease over losses of $(0.05) per share from
11-07 05:24
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2 to 5 years. ZORYVE is a once-daily, steroid-free topical treatment providing long-term disease control without duration restrictions. It effectively clears atopic dermatitis symptoms, including itch, and is safe for use on any body area. The product expands treatment options for children w...
10-30 12:00
PROSPERITY BANCSHARES, INC.® REPORTS THIRD QUARTER 2025 EARNINGS
Board approved increase in dividend of 3.45% to $0.60 per share for fourth quarter 2025, representing the 22nd consecutive annual increase, with a compound annual growth rate of 10.7% Net in...
10-29 18:30
SWIPE, EARN, AND FLY WITH SOUTHWEST AIRLINES' NEW RAPID REWARDS DEBIT CARD
Calling all budget-savvy travelers: Sign up to receive a welcome bonus and start earning points on everyday spending DALLAS, Oct. 28, 2025 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) ...
10-28 20:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
